News | Cardiovascular Ultrasound | November 14, 2019

FDA Clears AI-powered Cardiac Ultrasound Analysis and Quantification by Ultromics

EchoGo Core AI automates cardiac echo analysis helping earlier detection of cardiovascular disease

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

November 14, 2019 — Ultromics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its artificial intelligence (AI) driven echocardiography image analysis system EchoGo Core.

The FDA approval is a major milestone for U.K.-based Ultromics and enables the business to make EchoGo available to clinicians and healthcare providers in the United States. EchoGo applies AI to automate the analysis and quantification of cardiac ultrasound heart scans.

EchoGo has been years in development, from the first trial being set-up in 2011 to Ultromics spinning out of the University of Oxford in 2017, and now achieving FDA clearance. The next stage of growth is commercializing the product and making it available to clinicians.

Traditionally, echocardiography has relied on the expert eye of clinicians, with years of experience, measuring the anatomical structures and identifying the disease, a potentially time-consuming and highly variable process. By automating the process and applying its AI analysis to look in greater detail at the scans, EchoGo enables clinicians to interpret echocardiograms efficiently and accurately and assists in their decision-making.

EchoGo uses AI to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

“Strain has shown to be very valuable in cardiovascular diagnostics and has been demonstrated in published studies to be linked with earlier detection of disease and improved patient outcomes," said Ross Upton, founder and CEO of Ultromics. "Ultromics’ will be the first to use artificial intelligence for automated strain analysis which is applicable to 60 million scans per year. Crucially, strain is also becoming reimbursable from January 2020 in the U.S. EchoGo allows clinicians across a wide range of experience to rapidly obtain accurate and repeatable calculations of strain parameters, assisting them in interpretation of echocardiograms”.

The company has more developments in the pipeline for 2020, including EchoGo Pro. It will be the first AI system able to predict cardiac disease from echocardiography. Ultromics also is planning to expand into other geographic regions, including Europe and Asia. 

Ultromics has partnerships with leading cardiology clinical centers in the United States and 30 National Health System (NHS) centers in the U.K. Through this, it is continuously optimizing its scanning algorithms by analyzing the archive of scans held by these centers. The pipeline of AI algorithms underpinning EchoGo was built using thousands of images from a carefully curated dataset, from one of the largest echo studies of its kind.

EchoGo is a vendor-neutral platform, which integrates into the medical imaging environment, seamlessly providing clinicians with results as part of their routine diagnostic workflow. 

For more information: visit www.ultromics.com

Related Content

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

News | Cardio-oncology | February 25, 2021
February 25, 2020 — Results of a multi-centre, international, clinical trial co-led by Peter Munk Cardiac Centre (PMC
icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio
News | Artificial Intelligence | February 23, 2021
February 23, 2021 — icometrix, world leader in imaging...
GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

Feature | Ultrasound Imaging | February 18, 2021 | By Dave Fornell, Editor
Recent advances in ultrasound image sy...
Example MR images from paediatric brain tumour patients. This first column shows T1-weighted images following the injection of gadolinium contrast agent. The second column shows T2-weighted images and the final column shows apparent diffusion coefficient maps calculated from diffusion-weighted images. (a–c) are taken from a patient with a Pilocytic Astrocytoma, (d–f) are from a patient with an Ependymoma and (g–i) were acquired from a patient with a Medulloblastoma.

Example MR images from paediatric brain tumour patients. This first column shows T1-weighted images following the injection of gadolinium contrast agent. The second column shows T2-weighted images and the final column shows apparent diffusion coefficient maps calculated from diffusion-weighted images. (ac) are taken from a patient with a Pilocytic Astrocytoma, (df) are from a patient with an Ependymoma and (gi) were acquired from a patient with a Medulloblastoma. Image courtesy of Nature Research Journal

News | Pediatric Imaging | February 17, 2021
February 17, 2021 — Diffusio...
Insightec plans to expand in Latin America through a partnership with Strattner
News | Focused Ultrasound Therapy | February 16, 2021
February 16, 2021 — Insightec, a global healthcare company focused on creating the next generation of patient care, a
Brazilian researchers found that the higher the lung ultrasound score the greater the risk of ICU admission, intubation and death. Image courtesy of Julio Alencar

Brazilian researchers found that the higher the lung ultrasound score the greater the risk of ICU admission, intubation and death. Image courtesy of Julio Alencar

News | Coronavirus (COVID-19) | February 11, 2021
February 11, 2021 — ...
The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients
News | Artificial Intelligence | February 10, 2021
February 10, 2021 — Median Technologies announced the company has signed a research collaboration agreement with the
 Nuance Communications, Inc. announced the acquisition of Saykara, Inc., a like-minded startup focused on developing a mobile AI assistant to automate clinical documentation for physicians. The acquisition underscores Nuance's ongoing expansion of market and technical leadership in conversational artificial intelligence (AI) and ambient clinical intelligence (ACI) solutions that reduce clinician burnout, enhance patient experiences, and improve overall health system financial integrity.
News | Artificial Intelligence | February 08, 2021
February 8, 2021 — ...